CoChat
Sign Up
Cited by 152Glioma Diagnosis and TreatmentCancer survivorship and careOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Clinical Practice Experience With NovoTTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe)

Open access
Mrugala, Maciej M., Engelhard, Herbert H., Dinh Tran, David, Kew, Yvonne, Cavaliere, Robert, Villano, John L., Annenelie Bota, Daniela, Rudnick, Jeremy, Love Sumrall, Ashley, Zhu, Jay-Jiguang, Butowski, Nicholas·2014·Seminars in Oncology
DOI 10.1053/j.seminoncol.2014.09.010
Open this paper in CoChat — free account

Abstract

Recurrent glioblastoma multiforme (GBM) is a highly aggressive cancer with poor prognosis, and an overall survival of 6 to 7 months with optimal therapies. The NovoTTF-100A™ System is a novel antimitotic cancer therapy recently approved for the treatment of recurrent GBM, based on phase III (EF-11) trial results. The Patient Registry Dataset (PRiDe) is a post-marketing registry of all recurrent GBM patients who received NovoTTF Therapy in a real-world, clinical practice setting in the United States between 2011 and 2013. Data were collected from all adult patients with recurrent GBM who began commercial NovoTTF Therapy in the United States between October 2011 and November 2013. All patients provided written consent before treatment was started. Overall survival (OS) curves were constructed for PRiDe using the Kaplan-Meier method. Median OS in PRiDe was compared for patients stratified by average daily compliance (≥75% v<75% per day) and other prognostic variables. Adverse events were also evaluated. Data from 457 recurrent GBM patients who received NovoTTF Therapy in 91 US cancer centers were analyzed. More patients in PRiDe than the EF-11 trial received NovoTTF Therapy for first recurrence (33% v 9%) and had received prior bevacizumab therapy (55.1% v 19%). Median OS was significantly longer with NovoTTF Therapy in clinical practice (PRiDe data set) than in the EF-11 trial (9.6 v 6.6 months; HR, 0.66; 95% CI, 0.05 to 0.86, P = .0003). One- and 2-year OS rates were more than double for NovoTTF Therapy patients in PRiDe than in the EF-11 trial (1-year: 44% v 20%; 2-year: 30% v 9%). First and second versus third and subsequent recurrences, high Karnofsky performance status (KPS), and no prior bevacizumab use were favorable prognostic factors. No unexpected adverse events were detected in PRiDe. As in the EF-11 trial, the most frequent adverse events were mild to moderate skin reactions associated with application of the NovoTTF Therapy transducer arrays. Results from PRiDe, together with those previously reported in the EF-11 trial, indicate that NovoTTF Therapy offers clinical benefit to patients with recurrent GBM. NovoTTF Therapy has high patient tolerability and favorable safety profile in the real-world, clinical practice setting.

Overview

Integrity signals

Registry

Crossref · 10.1053/j.seminoncol.2014.09.010

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Kirson, 2010, Modeling tumor growth kinetics and its implications for TTFields treatment planning. [abstract], Neurooncology (Meeting Abstracts), 12

Cited by

Sorted by citations

See all 152

Related

See all

Metadata

Authors
Mrugala, M. M., Engelhard, H. H., Dinh Tran, D., Kew, Y., Cavaliere, R., Villano, J. L., Annenelie Bota, D., Rudnick, J., Love Sumrall, A., Zhu, J.-J., & Butowski, N.
Affiliations
  • University of Illinois Hospital & Health Sciences System (US)
  • Houston Methodist (US)
  • The Ohio State University (US)
  • University of Illinois Chicago (US)
  • Cedars-Sinai Medical Center (US)
  • The University of Texas Health Science Center at Houston (US)
  • University of California, San Francisco (US)
ORCID
Venue
Seminars in Oncology
Publisher
Elsevier BV
Published
2014-10
Volume
41
Pages
S4-S13
ISSN
0093-7754 (ISSN-L)
DOI
10.1053/j.seminoncol.2014.09.010
OpenAlex
W1994913111
Cited by
152
References
36
Citations by year
2026: 8 · 2025: 11 · 2024: 12 · 2023: 14 · 2022: 25 · 2021: 12 · 2020: 11 · 2019: 8 · 2018: 13 · 2017: 12 · 2016: 13 · 2015: 13
FWCI
6.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Seminars in Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords
overall survival, medication adherence, bevacizumab, prognostic factors, Karnofsky performance status, adverse events, skin reactions, real-world clinical practice, first recurrence
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Combined Modality Therapy, Electric Stimulation Therapy, Female, Follow-Up Studies, Glioblastoma, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Practice Patterns, Physicians', Prognosis, Registries, Survival Rate, Clinical Trials, Phase III as Topic, Young Adult, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review